Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiology

Journal of Molecular and Cellular Cardiology

Volumn 47, Issue 3, 2009, Pages 365-371

  Nicolaou, Persoulla ^a   Hajjar, Roger J ^b   Kranias, Evangelia G ^a,c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

Ca2+ cycling; Heart failure; Inhibitor 1; Phospholamban; Protein phosphatase 1; Sarcoplasmic reticulum

Indexed keywords

CARDIOVASCULAR AGENT; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PROTEIN KINASE C ALPHA; PROTEIN PHOSPHATASE 1 INHIBITOR 1; PROTEIN PHOSPHATASE 1 INHIBITOR 1C; UNCLASSIFIED DRUG;

CARDIOVASCULAR RISK; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; RISK FACTOR;

ANIMALS; CALCIUM; CALCIUM-BINDING PROTEINS; ENDOPLASMIC RETICULUM; FEMALE; GUINEA PIGS; HEART; HEART FAILURE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MODELS, BIOLOGICAL; PHOSPHORYLATION; SARCOPLASMIC RETICULUM; SUBSTRATE SPECIFICITY;

EID: 67650710788     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2009.05.010     Document Type: Review

References (74)

1. www.americanheart.org
2. Farkas E.A., and Elefteriades J.A. Assisted circulation: experience with the Novacor Left Ventricular Assist System. Expert. Rev. Med. Devices. 4 (2007) 769-774
3. Gwathmey J.K., Copelas L., MacKinnon R., Schoen F.J., Feldman M.D., Grossman W., et al. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ. Res. 61 (1987) 70-76
4. Hasenfuss G. Alterations of calcium-regulatory proteins in heart failure. Cardiovasc. Res. 37 (1998) 279-289
5. Beuckelmann D.J., Näbauer M., and Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 85 (1992) 1046-1055
6. Fabiato A., and Fabiato F. Calcium release from the sarcoplasmic reticulum. Circ. Res. 40 (1977) 119-129
7. Levitzki A. From epinephrine to cyclic AMP. Science 241 (1988) 800-806
8. Cohen P.T. Protein phosphatase 1-targeted in many directions. J. Cell. Sci. 115 (2002) 241-256
9. Ceulemans H., and Bollen M. Functional diversity of protein phosphatase-1, a cellular economizer and reset button. Physiol. Rev. 84 (2004) 1-39
10. Lesage B., Beullens M., Pedelini L., Garcia-Gimeno M.A., Waelkens E., Sanz P., et al. A complex of catalytically inactive protein phosphatase-1 sandwiched between Sds22 and inhibitor-3. Biochemistry 46 (2007) 8909-8919
11. MacDougall L.K., Jones L.R., and Cohen P. Identification of the major protein phosphatases in mammalian cardiac muscle which dephosphorylate phospholamban. Eur. J. Biochem. 196 (1991) 725-734
12. Steenaart N.A., Ganim J.R., Di Salvo J., and Kranias E.G. The phospholamban phosphatase associated with cardiac sarcoplasmic reticulum is a type 1 enzyme. Arch. Biochem. Biophys. 293 (1992) 17-24
13. Chu G., and Kranias E.G. Phospholamban as a therapeutic modality in heart failure. Novartis. Found. Symp. 274 (2006) 156-171
14. Mattiazzi A., Mundiña-Weilenmann C., Guoxiang C., Vittone L., and Kranias E. Role of phospholamban phosphorylation on Thr17 in cardiac physiological and pathological conditions. Cardiovasc. Res. 68 (2005) 366-375
15. Haghighi K., Gregory K.N., and Kranias E.G. Sarcoplasmic reticulum Ca-ATPase-phospholamban interactions and dilated cardiomyopathy. Biochem. Biophys. Res. Commun. 322 (2004) 1214-1222
16. MacLennan D.H., and Kranias E. Phospholamban: a crucial regulator of cardiac contractility. Nat. Rev. Mol. Cell. Biol. 4 (2003) 566-577
17. Kodama I., Kondo N., and Shibata S. Electromechanical effects of okadaic acid isolated from black sponge in guinea-pig ventricular muscles. J. Physiol. 378 (1986) 359-373
18. Neumann J., Boknik P., Herzig S., Schmitz W., Scholz H., Gupta R.C., et al. Evidence for physiological functions of protein phosphatases in the heart: evaluation with okadaic acid. Am. J. Physiol. 265 (1993) H257-H266
19. Neumann J., Bokník P., Herzig S., Schmitz W., Scholz H., Wiechen K., et al. Biochemical and electrophysiological mechanisms of the positive inotropic effect of calyculin A, a protein phosphatase inhibitor. J. Pharmacol. Exp. Ther. 271 (1994) 535-541
20. Neumann J., Herzig S., Boknik P., Apel M., Kaspareit G., Schmitz W., et al. On the cardiac contractile, biochemical and electrophysiological effects of cantharidin, a phosphatase inhibitor. J. Pharmacol. Exp. Ther. 274 (1995) 530-539
21. Linck B., Boknik P., Knapp J., Müller F.U., Neumann J., Schmitz W., et al. Effects of canthardin on force of contraction and phosphatase activity in nonfailing and failing human hearts. Br. J. Pharmacol. 119 (1996) 545-550
22. Carr A.N., Schmidt A.G., Suzuki Y., del Monte F., Sato Y., Lanner C., et al. Type 1 phosphatase, a negative regulator of cardiac function. Mol. Cell. Biol. 22 (2002) 4124-4135
23. Kirchhefer U., Baba H.A., Bokník P., Breeden K.M., Mavila N., Brüchert N., et al. Enhanced cardiac function in mice overexpressing protein phosphatase inhibitor-2. Cardiovasc. Res. 68 (2005) 98-108
24. Brüchert N., Mavila N., Boknik P., Baba H.A., Fabritz L., Gergs U., et al. Inhibitor-2 prevents protein phosphatase 1-induced cardiac hypertrophy and mortality. Am. J. Physiol. Heart Circ. Physiol. 295 (2008) H1539-H1546
25. Huang F.L., and Glinsmann W.H. Separation and characterization of two phosphorylase phosphatase inhibitors from rabbit skeletal muscle. Eur. J. Biochem. 70 (1976) 419-426
26. Aitken A., Bilham T., and Cohen P. Complete primary structure of protein phosphatase inhibitor-1 from rabbit skeletal muscle. Eur. J. Biochem. 126 (1982) 235-246
27. Foulkes J.G., and Cohen P. The hormonal control of glycogen metabolism. Phosphorylation of protein phosphatase inhibitor-1 in vivo in response to adrenaline. Eur. J. Biochem. 97 (1979) 251-256
28. Goldberg J., Huang H.B., Kwon Y.G., Greengard P., Nairn A.C., and Kuriyan J. Three-dimensional structure of the catalytic subunit of protein serine/threonine phosphatase-1. Nature 376 (1995) 745-753
29. Connor J.H., Quan H.N., Ramaswamy N.T., Zhang L., Barik S., Zheng J., et al. Inhibitor-1 interaction domain that mediates the inhibition of protein phosphatase-1. J. Biol. Chem. 273 (1998) 27716-27724
30. Connor J.H., Kleeman T., Barik S., Honkanen R.E., and Shenolikar S. Importance of the beta12-beta13 loop in protein phosphatase-1 catalytic subunit for inhibition by toxins and mammalian protein inhibitors. J. Biol. Chem. 274 (1999) 22366-22372
31. Watanabe T., Huang H.B., Horiuchi A., da Cruze Silva E.F., Hsieh-Wilson L., Allen P.B., et al. Protein phosphatase 1 regulation by inhibitors and targeting subunits. Proc. Natl. Acad. Sci. 98 (2001) 3080-3085
32. Egloff M.P., Johnson D.F., Moorhead G., Cohen P.T., Cohen P., and Barford D. Structural basis for the recognition of regulatory subunits by the catalytic subunit of protein phosphatase 1. EMBO. J. 16 (1997) 1876-1887
33. Brown G.P., Blitzer R.D., Connor J.H., Wong T., Shenolikar S., Iyengar R., et al. Long-term potentiation induced by theta frequency stimulation is regulated by a protein phosphatase-1-operated gate. J. Neurosci. 20 (2000) 7880-7887
34. Connor J.H., Weiser D.C., Li S., Hallenbeck J.M., and Shenolikar S. Growth arrest and DNA damage-inducible protein GADD34 assembles a novel signaling complex containing protein phosphatase 1 and inhibitor 1. Mol. Cell. Biol. 21 (2001) 6841-6850
35. Nakielny S., Campbell D.G., and Cohen P. The molecular mechanism by which adrenalin inhibits glycogen synthesis. Eur. J. Biochem. 199 (1991) 713-722
36. Foulkes J.G., Cohen P., Strada S.J., Everson W.V., and Jefferson L.S. Antagonistic effects of insulin and beta-adrenergic agonists on the activity of protein phosphatase inhibitor-1 in skeletal muscle of the perfused rat hemicorpus. J. Biol. Chem. 257 (1982) 12493-12496
37. Foulkes J.G., Strada S.J., Henderson P.J., and Cohen P. A kinetic analysis of the effects of inhibitor-1 and inhibitor-2 on the activity of protein phosphatase-1. Eur. J. Biochem. 132 (1983) 309-313
38. Ahmad Z., Green F.J., Subuhi H.S., and Watanabe A.M. Autonomic regulation of type 1 protein phosphatase in cardiac muscle. J. Biol. Chem. 264 (1989) 3859-3863
39. Neumann J., Gupta R.C., Schmitz W., Scholz H., Nairn A.C., and Watanabe A.M. Evidence for isoproterenol-induced phosphorylation of phosphatase inhibitor-1 in the intact heart. Circ. Res. 69 (1991) 1450-1457
40. Iyer R.B., Koritz S.B., and Kirchberger M.A. A regulation of the level of phosphorylated phospholamban by inhibitor-1 in rat heart preparations in vitro. Mol. Cell. Endocrinol. 55 (1988) 1-6
41. Gupta R.C., Neumann J., Watanabe A.M., Lesch M., and Sabbah H.N. Evidence for presence and hormonal regulation of protein phosphatase inhibitor-1 in ventricular cardiomyocyte. Am. J. Physiol. 270 (1996) H1159-H1164
42. El-Armouche A., Wittköpper K., Degenhardt F., Weinberger F., Didié M., Melnychenko I., et al. Phosphatase inhibitor-1-deficient mice are protected from catecholamine-induced arrhythmias and myocardial hypertrophy. Cardiovasc. Res. 80 (2008) 396-406
43. El-Armouche A., Rau T., Zolk O., Ditz D., Pamminger T., Zimmermann W.H., et al. Evidence for protein phosphatase inhibitor-1 playing an amplifier role in beta-adrenergic signaling in cardiac myocytes. FASEB J. 1 (2003) 437-439
44. Pathak A., del Monte F., Zhao W., Schultz J.E., Lorenz J.N., Bodi I., et al. Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ. Res. 96 (2005) 756-766
45. Nicolaou P., Rodriguez P., Ren X., Zhou X., Qian J., Sadayappan S., et al. Inducible expression of active protein phosphatase-1 inhibitor-1 enhances basal cardiac function and protects against ischemia/reperfusion injury. Circ. Res. 104 8 (2009) 1012-1020
46. El-Armouche A., Bednorz A., Pamminger T., Ditz D., Didié M., Dobrev D., et al. Role of calcineurin and protein phosphatase-2A in the regulation of phosphatase inhibitor-1 in cardiac myocytes. Biochem. Biophys. Res. Commun. 346 (2006) 700-706
47. Huang K.X., and Paudel H.K. Ser67-phosphorylated inhibitor 1 is a potent protein phosphatase 1 inhibitor. Proc. Natl. Acad. Sci. 97 (2000) 5824-5829
48. Bibb J.A., Nishi A., O'Callaghan J.P., Ule J., Lan M., Snyder G.L., et al. Phosphorylation of protein phosphatase inhibitor-1 by Cdk5. J. Biol. Chem. 276 (2001) 14490-14497
49. Sahin B., Shu H., Fernandez J., El-Armouche A., Molkentin J.D., Nairn A.C., et al. Phosphorylation of protein phosphatase inhibitor-1 by protein kinase C. J. Biol. Chem. 281 (2006) 24322-24335
50. Braz J.C., Gregory K., Pathak A., Zhao W., Sahin B., Klevitsky R., et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat. Med. 10 (2004) 248-254
51. Rodriguez P., Mitton B., Waggoner J.R., and Kranias E.G. Identification of a novel phosphorylation site in protein phosphatase inhibitor-1 as a negative regulator of cardiac function. J. Biol. Chem. 281 (2006) 38599-38608
52. Rodriguez P., Mitton B., Nicolaou P., Chen G., and Kranias E.G. Phosphorylation of human inhibitor-1 at Ser67 and/or Thr75 attenuates stimulatory effects of protein kinase A signaling in cardiac myocytes. Am. J. Physiol. Heart Circ. Physiol. 293 (2007) H762-H769
53. Barki-Harrington L., Perrino C., and Rockman H.A. Network integration of the adrenergic system in cardiac hypertrophy. Cardiovasc. Res. 63 (2004) 391-402
54. Ferguson S.S. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol. Rev. 53 (2001) 1-24
55. Neumann J., Eschenhagen T., Jones L.R., Linck B., Schmitz W., Scholz H., et al. Increased expression of cardiac phosphatases in patients with end-stage heart failure. J. Mol. Cell. Cardiol. 29 (1997) 265-272
56. Mishra S., Gupta R.C., Tiwari N., Sharov V.G., and Sabbah H.N. Molecular mechanisms of reduced sarcoplasmic reticulum Ca(2+) uptake in human failing left ventricular myocardium. J. Heart Lung Transplant 21 (2002) 366-373
57. Huang B., Wang S., Qin D., Boutjdir M., and El-Sherif N. Diminished basal phosphorylation level of phospholamban in the postinfarction remodeled rat ventricle: role of beta-adrenergic pathway, G (i) protein, phosphodiesterase, and phosphatases. Circ. Res. 85 (1999) 848-855
58. Sande J.B., Sjaastad I., Hoen I.B., Bøkenes J., Tønnessen T., Holt E., et al. Reduced level of serine(16) phosphorylated phospholamban in the failing rat myocardium: a major contributor to reduced SERCA2 activity. Cardiovasc. Res. 53 (2002) 382-391
59. Bokník P., Fockenbrock M., Herzig S., Knapp J., Linck B., Lüss H., et al. Protein phosphatase activity is increased in a rat model of long-term beta-adrenergic stimulation. Naunyn-Schmiedeberg's Arch. Pharmacol. 362 (2000) 222-231
60. Gupta R.C., Mishra S., Yang X.P., and Sabbah H.N. Reduced inhibitor 1 and 2 activity is associated with increased protein phosphatase type 1 activity in left ventricular myocardium of one-kidney, one-clip hypertensive rats. Mol. Cell. Biochem. 269 (2005) 49-57
61. Gupta R.C., Mishra S., Rastogi S., Imai M., Habib O., and Sabbah H.N. Cardiac SR-coupled PP1 activity and expression are increased and inhibitor 1 protein expression is decreased in failing hearts. Am. J. Physiol. Heart Circ. Physiol. 285 (2003) H2373-H2381
62. El-Armouche A., Pamminger T., Ditz D., Zolk O., and Eschenhagen T. Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts. Cardiovasc. Res. 61 (2004) 87-93
63. Wilkins B.J., and Molkentin J.D. Calcineurin and cardiac hypertrophy: where have we been? Where are we going?. J. Physiol. 541 (2002) 1-8
64. Bowling N., Walsh R.A., Song G., Estridge T., Sandusky G.E., Fouts R.L., et al. Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. Circulation 99 (1999) 384-391
65. El-Armouche A., Gocht F., Jaeckel E., Wittköpper K., Peeck M., and Eschenhagen T. Long-term beta-adrenergic stimulation leads to downregulation of protein phosphatase inhibitor-1 in the heart. Eur. J. Heart. Fail. 9 (2007) 1077-1080
66. Chen G., Zhou X., Nicolaou P., Rodriguez P., Song G., Mitton B., et al. A human polymorphism of protein phosphatase-1 inhibitor-1 is associated with attenuated contractile response of cardiomyocytes to {beta}-adrenergic stimulation. FASEB J. 22 (2008) 1790-1796
67. El-Armouche A., Boknik P., Eschenhagen T., Carrier L., Knaut M., Ravens U., et al. Molecular determinants of altered Ca2+ handling in human chronic atrial fibrillation. Circulation 114 (2006) 670-680
68. Dorn 2nd G.W., and Molkentin J.D. Manipulating cardiac contractility in heart failure: data from mice and men. Circulation 109 (2004) 150-158
69. Zhang T., Maier L.S., Dalton N.D., Miyamoto S., Ross Jr. J., Bers D.M., et al. The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ. Res. 92 (2003) 912-919
70. Kirchhefer U., Schmitz W., Scholz H., and Neumann J. Activity of cAMP-dependent protein kinase and Ca2+/calmodulin-dependent protein kinase in failing and nonfailing human hearts. Cardiovasc. Res. 42 (1999) 254-261
71. Wehrens X.H., Lehnart S.E., Reiken S.R., Deng S.X., Vest J.A., Cervantes D., et al. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science 304 (2004) 292-296
72. Yano M., Ono K., Ohkusa T., Suetsugu M., Kohno M., Hisaoka T., et al. Altered stoichiometry of FKBP12.6 versus ryanodine receptor as a cause of abnormal Ca (2+) leak through ryanodine receptor in heart failure. Circulation 102 (2000) 2131-2136
73. Wehrens X.H., Lehnart S.E., Reiken S.R., and Marks A.R. Ca2+/calmodulin-dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor. Circ. Res. 94 (2004) e61-70
74. Curran J., Hinton M.J., Ríos E., Bers D.M., and Shannon T.R. Beta-adrenergic enhancement of sarcoplasmic reticulum calcium leak in cardiac myocytes is mediated by calcium/calmodulin-dependent protein kinase. Circ. Res. 100 (2007) 391-398